AESOP TECHNOLOGY
  • DxPro
    • DxPrime
    • DxCode
  • Medigator
    • Oncology
    • More Therapeutic Areas
  • RxPrime
  • Research
  • AESOP Talks
  • News
  • About
  • 中文

PharmStars Announces Spring 2025 Graduates: 12 Digital Health Startups Complete PharmStars’ Pharma-focused Accelerator

6/17/2025

 
Picture
PharmStars
Picture
PharmStars Accelerator Spring 2025 Startup Graduates
PharmStars, the pharma-focused accelerator for digital health startups, is delighted to announce that 12 startups graduated from its Spring 2025 program focusing on “Digital Innovations in Rare Disease.” The graduating startups completed PharmaU, PharmStars’ 10-week educational and mentoring program. PharmaU culminated recently with a Showcase Event in Boston that brought together participating startups and PharmStars’ innovation-minded pharma members.

PharmStars is dedicated to bridging the "pharma-startup gap." The accelerator's mission is to help biopharma firms and digital health startups overcome barriers to partnership due to differences in size, speed, processes, and culture, thereby accelerating the adoption of digital innovations to improve patient outcomes. PharmaU prepares participating startups to effectively engage with pharma companies as clients and partners.

The 12 startups were selected in March through a highly competitive application process that attracted applicants from 10 countries. The startups offer unique digital health innovations for rare disease, including diagnostics and biomarkers for patient identification and disease monitoring, tools to improve the execution of rare disease clinical trials, and patient research and advocacy group solutions.

The graduating startups were thrilled with their PharmaU education. Jan-Willem Hoste, CEO of Meep and a Spring 2025 PharmStars graduate said, “After putting into practice the mentoring and education we received from PharmStars, we noticed the difference in how our value proposition was received during our sales discussions — we could get to the essence quicker as we spoke their language and understood pharma’s challenges in a deeper way. PharmaU got us there!”

Anna Chukaeva, CEO of Intercellular, and another Spring 2025 graduate, concurred, “I'm really thankful for PharmStars. I got more than I ever expected. With most accelerators, the value is signaling: you got accepted into the accelerator and exposure at demo day, but that's it. PharmStars does way more. Through PharmaU, we learned a lot, worked closely with amazing mentors, and started meaningful conversations with potential customers.”

At the Showcase Event, startups presented their solutions to PharmStars’ pharma members and then met with them individually. More than 70 private, one-on-one startup/pharma meetings took place over two days.

The opportunity to connect with pharmaceutical stakeholders is incredibly impactful, explained Spring 2025 graduate, Amanda Clark, CEO of PulManage, “The fireside chats helped us understand the pharma members. When we got to see them at the Showcase, the groundwork had already been laid so we could start conversations, continue them in the one-on-one meetings, and build relationships.”

The 12 digital health startups completing the Spring 2025 PharmStars accelerator are:
  • AESOP Technology (San Francisco, CA) – Dashboard for Real-Time EHR Data Insights
  • Comend (Toronto, Canada) – Federated Marketplace of Rare Disease Patient Advocacy Groups and Their Biosamples, Studies, and IP
  • Compose Health (Ottawa, Canada) – AI Orchestration Platform for Rapid Market-Facing Content Production
  • EXOSYSTEMS (Seongnam-si, Korea) – AI Digital Biomarker Platform for Quantitative, Objective Motor Function Assessment
  • Global Key Solutions (New York, NY) – Continuously Updated Information Engine to Access Industry-Wide Compliance and Regulatory Data
  • Intercellular (San Francisco, CA) – AI-enabled miRNA Platform for Cancer Monitoring
  • LivAi (San Francisco, CA) – AI Platform Transforming Routine Imaging into 3D, Quantitative Tumor Biomarkers
  • Meep (Ghent, Belgium) – Clinical-Grade, At-Home Biomarker Minilab for Measuring Daily Disease Activity, Drug Levels and Organ Function
  • Octozi (New York, NY) – AI-Enabled Data Cleaning and Review Platform
  • Preview Health (Sydney, Australia) – Complete Metabolic-Profiling AI Platform for Precision Medicine
  • PulManage (Chapin, SC) – Scalable Platform for Real-time, High-quality, Remote Spirometry
  • Vako (New York, NY) – Platform to Unify Patient Advocacy Groups and Support Their Patients

PharmStars is now open for applications for its upcoming Fall 2025 cohort focused on “Innovations in Data Management and Insights.” New pharma and biotech members are welcome to join the program. Digital health startups interested in participating can find additional details and the application on PharmStars’ website, www.PharmStars.com.

About PharmStars
PharmStars is the member-based, pharma-focused accelerator for digital health startups. Because of our expertise across pharma, startups, digital health, and innovation, we understand the challenges that pharma and startups face when seeking to collaborate. Our PharmaU program supports digital health startups and our pharma members in “bridging the pharma-startup gap,” leading to greater success and faster adoption of “beyond the molecule” solutions. More information at www.PharmStars.com.

Reference:
PharmStars

AI-Powered CDSS Enhances Patient Safety with Real-World Data

6/17/2025

 
PRN Logo
The growing demand for personalized medicine has accelerated the adoption of Real-World Data (RWD) in healthcare. The Tungs' Taichung MetroHarbor Hospital in Taiwan, in collaboration with AESOP Technology, conducted research on an AI-driven Clinical Decision Support System (CDSS) that leverages RWD to enable safer and more effective clinical decision-making, significantly reducing the risk of potentially inappropriate medications. The findings were published in the Journal of Medical Internet Research recently.

RWD encompasses various data types, including electronic health records (EHR), insurance claims, wearable devices, environmental factors, and social determinants of health. It offers a comprehensive view of patient conditions and treatment outcomes. However, effectively utilizing RWD remains a significant challenge.

As a key component of RWD, the EHR system is often constrained by the poor design of traditional CDSS. These systems frequently fire irrelevant or low-priority alerts and fail to provide specific recommendations for complex scenarios, such as off-label drug use, multimorbidity, and polypharmacy. This results in alert fatigue among physicians, causing critical alerts and reminders to be overlooked. Consequently, the completeness and accuracy of medical records are compromised, increasing the risk of inappropriate diagnoses or treatments and potentially threatening patient safety.

This study addresses these challenges with an integrated AI-powered CDSS that combines MedGuard (now called RxPrime) for prescription appropriateness and DxPrime for diagnostic recommendations. By analyzing 438,558 prescriptions during a year-long trial, the system delivered 10,006 actionable recommendations, achieving a nearly 60% acceptance rate by physicians. Compared to traditional systems, this AI-enhanced approach demonstrated superior precision and practical applicability in real-world clinical settings.

The results also revealed high acceptance rates in specialties such as ophthalmology (96.59%) and obstetrics/gynecology (90.01%), indicating strong applicability. In contrast, lower acceptance rates in neurology (38.54%) and hematology-oncology (10.94%) underscore the need for specialty-specific customization to address diverse clinical demands.

This research highlights the transformative potential of RWD-driven AI systems with actionable recommendations to improve patient safety and support complex treatment decisions. These advancements foster greater trust and adoption of CDSS by physicians. Furthermore, by enhancing the completeness and accuracy of medical records, these systems elevate the quality of RWD, fostering a positive feedback loop that drives future medical advancements and consistently provides a reliable foundation for data-driven healthcare.

AESOP Technology Unveils World's First Machine Learning Model to Combat Wrong-Site Surgery

2/18/2025

 
Picture
Wrong-site surgery (WSS), a critical "Never Event," represents a failure that should never occur in healthcare. Yet, due to underreporting, the true prevalence of these incidents remains obscured, jeopardizing patient safety and healthcare management. AESOP Technology, a medical AI startup, has developed an innovative solution: the Association Outlier Pattern (AOP) machine learning model. This model offers real-time decision support and retrospective analysis, aimed at enhancing surgical safety and care quality.

According to the World Health Organization's (WHO) 2024 Patient Safety Report, a mere 38% of countries have established reporting systems for never events. In the United States, the Joint Commission documented 112 surgical errors in 2023, with wrong-site surgeries comprising 62% of these incidents. The absence of comprehensive reporting hinders the healthcare system's ability to gauge the issue's magnitude and implement effective preventative measures.

Inconsistent documentation is one of the major contributors to WSS. To address this, AESOP utilized data from the Centers for Medicare & Medicaid Services Limited Data Set (2017–2020), examining discrepancies in surgical laterality. This analysis informed the creation of the AOP model—the first of its kind dedicated to addressing WSS.

Unlike traditional rule-based systems that merely verify consistency, the AOP model analyzes intricate patterns between diagnoses and surgeries. It excels in handling incomplete or ambiguous diagnostic data, achieving an accuracy rate of over 80% in identifying surgical errors, outperforming existing methods.

The AOP model empowers healthcare organizations to detect inconsistencies in medical records, identify unreported surgical errors, and enhance reporting mechanisms. This not only improves patient safety but also strengthens management systems for error prevention.

Beyond retrospective analysis, the AOP model offers real-time decision support during surgical planning. It automatically flags incorrect associations between surgical codes and diagnoses, ensuring accurate and complete records. This real-time capability reduces error risks, making the AOP model an essential tool for future electronic health record (EHR) systems.

"We are thrilled with the preliminary outcomes of our research and look forward to integrating these insights into DxPrime's patient safety features this year," said Jim Long, CEO of AESOP Technology. "Our advancements in automating surgery coding show great potential for helping physicians deliver safer care, reduce documentation time, and enable medical coders to perform better concurrent surgery coding and review when patients are still hospitalized."

Having demonstrated its efficacy in orthopedics, the AOP model holds promise for other specialties reliant on laterality, such as ophthalmology and otolaryngology. This expansion aligns with AESOP's commitment to advancing patient-centered AI solutions across diagnostics, medication safety, and now surgical safety—ushering in a new era of reliable and safer healthcare.
​

    Picture

    ​

    All
    2019
    2020
    2021
    2022
    2023
    2024
    2025
    #BENZINGA
    #Business Startup Award
    #COMPUTEX Taipei
    #EE Times Asia
    #FOCUS TAIWAN
    #HEALTHCARE REPORT
    #Mayo Clinic Platform_Accelerate
    #MobiHealthNews
    #Olive Hack For Health
    #PharmStars
    #PR Newswire
    #Taipei Biotech Awards
    #Taiwan Business TOPICS
    #Taiwan Research Highlight
    #Yahoo Finance

    More News in Chinese
AESOP TECHNOLOGY
[email protected]
​Privacy Policy
© AESOP Technology 2025
  • DxPro
    • DxPrime
    • DxCode
  • Medigator
    • Oncology
    • More Therapeutic Areas
  • RxPrime
  • Research
  • AESOP Talks
  • News
  • About
  • 中文